Rausch C, Hoffmann F. Prescribing medications of questionable benefit prior to death: a retrospective study on older nursing home residents with and without dementia in Germany. Eur J Clin Pharmacol 2020;76:877-85. [Ref.ID 103645]

Jayadevappa R, Chhatre S, Malcowikz B, Parikh RB, Guzzo T, Wein AJ. Association between androgen deprivation therapy use and diagnosis of dementia in men with prostate cancer. JAMA Network Open 2019;2:e196562. [Ref.ID 103156]

Williams CL, Jones ME, Swerdlow AJ, Botting BJ, Davies MC, Jacobs I, Bunch KJ, Murphy MFG, Sutcliffe AG. Risks of ovarian, breast, and corpus uteri cancer in women treated with assisted reproductive technology in Great Britain, 1991-2010: data linkage study including 2.2 million person years of observation. BMJ 2018;362:k2644. [Ref.ID 102818]

Anónimo. Flutamida: casos graves de hepatotoxicidad asociados al uso fuera de las condiciones autorizadas. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2017:27 de abril. [Ref.ID 101552]

Nead KT, Gaskin G, Chester C, Swisher-McClure S, Leeper NJ, Shah NH. Association between androgen deprivation therapy and risk of dementia. JAMA Oncology 2016:13 de octubre. [Ref.ID 100814]

O'Dowd A. Drug company is suspended from UK industry body after “deception on a grand scale”. BMJ 2016;353:i3574. [Ref.ID 100449]

D'Amico AV, Chen M-H, Renshaw A, Loffredo M, Kantoff PW. Long-term follow-up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA 2015;314:1291-3. [Ref.ID 99525]

Moore HCF, Unger JM, Phillips K-A, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gómez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens Jr FL, Gelber RD, Hortobagyi GN, Albain KS, for the POEMS/S0230 Investigators. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015;372:923-32. [Ref.ID 98930]

Johansson JE, Andrén O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, Adami HO. Natural history of early, localized prostate cancer. JAMA 2014;291:2713-9. [Ref.ID 97706]

Hickey M, Ballard K, Farquhar C. Endometriosis. BMJ 2014;348:g1752. [Ref.ID 97481]

Muneer A, Kalsi J, Nazareth I, Arya M. Erectile dysfunction. BMJ 2014;348:g129. [Ref.ID 97218]

Anónimo. Fibromyomes utérins hémorragiques. Adapter le traitement à chaque femme. Prescrire 2014;34:115-22. [Ref.ID 97129]

Lapi F, Azoulay L, Niazi MT, Yin H, Benayoun S, Suissa S. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer. JAMA 2013;310:289-96. [Ref.ID 95834]

Hyde R. Germany launches investigation into human trials scandal. Lancet 2013;382:115-6. [Ref.ID 95826]

Anónimo. Traiter (ou non) les cancers localisés de la prostate. Choisir entre surveillance, chirurgie, ou radiothérapie, selon l'évolution naturelle, souvent peu défavorable. Prescrire 2012;32:362-8. [Ref.ID 92814]

Stewart EA. Uterine fibroids and evidence-based medicine - Not an oxymoron. N Engl J Med 2012;366:471-3. [Ref.ID 92307]

Donnez J, Tomaszewski J, Vázquez F, Bouchard P, Lemieszczuk B, Baró F, Kouri K, Selvaggi L, Sodowski K, Bestel E, Terrill P, Osteroh I, Loumaye E, for the PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012;366:421-32. [Ref.ID 92305]

Kelly WK, Gomella LG. Androgen deprivation therapy and competing risks. JAMA 2011;306:2382-3. [Ref.ID 91670]

Anónimo. Prises de poids d'origine médicamenteuse. Prescrire 2011;31:748-52. [Ref.ID 91601]

Anónimo. Histréline. Nième agoniste de la gonadoréline, sans plus. Prescrire 2011;31:728. [Ref.ID 91595]